Fundraising FoxImmunoMolecular Therapeutics
Aurora, US · Founded 2015 · Delaware corporation · 1 known investors
Find your way into ImmunoMolecular Therapeutics
Sign up to see every warm intro you have to ImmunoMolecular Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ImmunoMolecular Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
PG
SO
Steve OrndorffNamed on SEC filing
Board
EO
Ed OrrBoard director
Investors · 1
JDRF T1D FundreportedBoston
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10.8M disclosed across 4 rounds · 2015–2020
▶$7MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$7MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter GottliebExecutive Officer, Director
- Ed OrrDirector
- Sean DohertyDirector
- Tom SheaExecutive Officer
- Aaron MichelsExecutive Officer
- Nandan PadukoneExecutive Officer, Director
- Jason DingesDirector
- Offering amount
- $10M
- Amount sold
- $7M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJun 2019 · 7 investors · BiotechnologyRule 506(b)
▶$3MraisedJun 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter GottliebExecutive Officer, Director, Promoter
- Ed OrrDirector, Promoter
- Jonathan BehrDirector
- Jason DingesDirector
- Aaron MichelsPromoter
- Offering amount
- $10M
- Amount sold
- $3M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$350KraisedAug 2016 · 1 investors · BiotechnologyRule 506(b)
▶$350KraisedAug 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron MichelsPromoter
- Peter GottliebDirector, Promoter
- Steve OrndorffExecutive Officer, Director, Promoter
- Ed OrrDirector, Promoter
- Offering amount
- $3M
- Amount sold
- $350K
- First sale
- Jul 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$500KraisedJun 2015 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron MichelsPromoter
- Ed OrrDirector, Promoter
- Peter GottliebDirector, Promoter
- Steve OrndorffExecutive Officer, Director, Promoter
- Offering amount
- $1.2M
- Amount sold
- $500K
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are ImmunoMolecular Therapeutics's investors?
- ImmunoMolecular Therapeutics's investors include JDRF T1D Fund.
- How much funding has ImmunoMolecular Therapeutics raised?
- ImmunoMolecular Therapeutics has disclosed $10.8M raised across 4 rounds.
- Where is ImmunoMolecular Therapeutics headquartered?
- ImmunoMolecular Therapeutics is headquartered in Aurora, US.